2nd Annual Hemophilia Drug Development (HDD) Summit

Event Date: August 20 - 22, 2019

Event Location: Wyndham Boston Beacon Hill, 5 Blossom St, Boston, MA 02114

 

Diapharma will attend the 2nd Annual Hemophilia Drug Development (HDD) Summit this year. Please click here to schedule a meeting with us or email us directly.

About the HDD

The 2nd Annual Hemophilia Drug Development Summit is dedicated to translating more effective therapies, bringing the right treatments to meet the goals of every subject. From subcutaneous therapies to gene therapies these all have the aim of improving subjects’ quality of life.

This event brings together over 100 of the world’s leading experts and drug developers. They will discuss the development and impact of non-factor products, patient advocacy and engagement strategies, improve testing methods and assays for better measures of response and diagnosis, and the payer and reimbursement strategies to ensure market access.

Workshops

Workshop A

Understanding Immunogenicity in Next Generation Factor Replacement Prophylaxis

Workshop B

Improving Patient Access to Gene Therapy Through Novel Payer and Reimbursement Strategies

Topics

  • Evaluating the impact of non-factor products in a changing hemophilia treatment paradigm
  • Assessing the impact of new therapies on hemophilia patients
  • Clinical development of Concizumab, a monoclonal antibody for subcutaneous prophylaxis for all hemophilia patients
  • American thrombosis and hemostasis network – a national collaborative
  • Application of state-of-the-art laboratory techniques to an ever-changing hemophilia drug landscape
  • Fitusiran, an RNAi therapeutic targeting antithrombin to restore hemostatic balance in people with hemophilia
  • Advancing novel prophylaxis that improves quality of life
  • A tale of two subcutaneous coagulation factors
  • Thrombin generation assay (TGA): one of the most versatile tools in the coagulation assay tool chest
  • Research and development of next generation prophylaxis
  • Significance of neutralizing antibodies in gene therapy in hemophilia
  • Emerging roles of transgene mutations in gene therapy products for hemophilia
  • A stable & durable treatment for pediatric patients with hemophilia
  • Preliminary data for SB-525 for the treatment of severe hemophilia A
  • Data from a prospective study using FVIIIFc for ITI in hemophilia patients with inhibitors
  • Women’s health in von Willebrand Disease
  • Patient advocacy and improving diagnosis of von Willebrand Disease
  • Challenges and considerations in medical affairs for novel hemophilia drug development

HDD | Twitter | Wyndham Boston